Commercialization Consultant at Pharma/Biotech Industry
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Pharma/Biotech Industry since Oct 2012
Commercialization Consultant
Cyclacel Pharmaceuticals Inc - Berkeley Heights, NJ Apr 2008 - 2012
Vice President, Sales and Marketing
Genentech Apr 2004 - Apr 2008
Senior Thought Leader Liaison
DexGen Pharmaceuticals, Inc. Jan 2001 - Apr 2004
President and CEO; Founding Partner
Algos Pharmaceuticals Jan 1999 - Jan 2001
Vice President, Sales and Marketing
Education:
University of Connecticut School of Medicine 1980 - 1982
The University of Connecticut 1976 - 1980
Bachelor of Science, Biology
Awards:
2006-2007 MVP Her Family Award Genentech Honored by sales force management 2005-2006 Beacon Award for Most Impactful Relationship with Sales Organization Genentech 2004 TLL of Year Genentech Honored by sales force management
Robert E. Sosnowski - Manasquan NJ Philip C. Lang - Toms River NJ
Assignee:
DexGen Pharmaceuticals, Inc. - Manasquan NJ
International Classification:
A61K 3144
US Classification:
514289, 514284, 514282, 514249, 514185, 4241951
Abstract:
Elevated levels of homocysteine have been implicated as an important risk factor for cardiovascular and other diseases. A composition for decreasing levels of plasma homocysteine and a method for administering the composition are provided the composition containing dextromethorphan (DM), folic acid and vitamins B and B. The composition provides a synergistic therapeutic effect so that lower amounts of the above ingredients may be employed to minimize any undesirable side effects caused by the use of high levels of a component such as DM. Preferred compositions for cardiovascular diseases further include lecithin, vitamin E, beta-carotene, procyanidins/flavonoids, trimethylglycine, garlic oil and minerals. Other compositions for treating glaucoma include bilberry, bioflavonoids and beta-carotene and for treating tardive dyskinesia include an antioxidant such as grape seed extract and pine bark extract, lecithin and oligomeric proanthocyanidins. The compositions may be administered using any suitable means such as orally or intravenous.
Composition And Method For Reducing The Risk Or Progression Of Cardiovascular, Glaucoma And Tardive Dyskinesia Diseases
Robert Sosnowski - Manasquan NJ, US Philip Lang - Toms River NJ, US
International Classification:
A61K031/00
US Classification:
514/001000
Abstract:
Elevated levels of homocysteine have been implicated as an important risk factor for cardiovascular and other diseases. A composition for decreasing levels of plasma homocysteine and a method for administering the composition are provided the composition containing dextromethorphan (DM), folic acid and vitamins Band B. The composition provides a synergistic therapeutic effect so that lower amounts of the above ingredients may be employed to minimize any undesirable side effects caused by the use of high levels of a component such as DM. Preferred compositions for cardiovascular diseases further include lecithin, vitamin E, beta-carotene, procyanidins/flavonoids, trimethylglycine, garlic oil and minerals. Other compositions for treating glaucoma include bilberry, bioflavonoids and beta-carotene and for treating tardive dyskinesia include an antioxidant such as grape seed extract and pine bark extract, lecithin and oligomeric proanthocyanidins. The compositions may be administered using any suitable means such as orally or intravenous.
Composition And Method For Reducing The Risk Or Progression Of Cardiovascular, Glaucoma And Tardive Dyskinesia Diseases
Robert Sosnowski - Manasquan NJ, US Philip Lang - Toms River NJ, US
International Classification:
A61K031/00
US Classification:
514/001000
Abstract:
Elevated levels of homocysteine have been implicated as an important risk factor for cardiovascular and other diseases. A composition for decreasing levels of plasma homocysteine and a method for administering the composition are provided the composition containing dextromethorphan (DM), folic acid and vitamins Band B. The composition provides a synergistic therapeutic effect so that lower amounts of the above ingredients may be employed to minimize any undesirable side effects caused by the use of high levels of a component such as DM. Preferred compositions for cardiovascular diseases further include lecithin, vitamin E, beta-carotene, procyanidins/flavonoids, trimethylglycine, garlic oil and minerals. Other compositions for treating glaucoma include bilberry, bioflavonoids and beta-carotene and for treating tardive dyskinesia include an antioxidant such as grape seed extract and pine bark extract, lecithin and oligomeric proanthocyanidins. The compositions may be administered using any suitable means such as orally or intravenous.
Composition And Method For Reducing The Risk Or Progression Of Cardiovascular, Glaucoma, Tardive Dyskinesia And Other Diseases
Robert Sosnowski - Manasquan NJ, US Philip Lang - Toms River NJ, US
International Classification:
A61K031/00
US Classification:
514/001000
Abstract:
Elevated levels of homocysteine have been implicated as an important risk factor for cardiovascular and other diseases. A composition for decreasing levels of plasma homocysteine and a method for administering the composition are provided, the composition containing dextromethorphan (DM), folic acid and vitamins Band B. The composition provides a synergistic therapeutic effect so that lower amounts of the above ingredients may be employed to minimize any undesirable side effects caused by the use of high levels of a component such as DM. Preferred compositions for cardiovascular diseases further include lecithin, vitamin E, betacarotene, procyanidins/flavonoids, trimethylglycine, garlic oil and minerals. Other compositions for treating glaucoma include bilberry, bioflavonoids and beta-carotene and for treating tardive dyskinesia include an antioxidant such a grape seed extract and pine bark extract, lecithin and oligomeric proanthocyanidins. The compositions may be administered using any suitable means such as orally or intravenous.